Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged…